M&A · Healthcare · Pharmaceutical Preparations
Sanofi to acquire Blueprint Medicines Corp
Announced Jun 2, 2025 · Closed Jul 18, 2025
Deal value$9.10BEV $8.98B
Premium27.0%To unaffected price
EV / Adj. EBITDA—16.0x EV / Revenue
ConsiderationAll cash$129.00 per share
Transaction
- Acquirer
- Sanofi (SNY)
- Target
- Blueprint Medicines Corp (BPMC)
- Buyer type
- Strategic
- Offer price per share
- $129.00
- Enterprise value
- $8.98B
- Status
- Closed Jul 18, 2025
Deal protections
- Break fee (target pays)
- $318M · 3.5%
- Reverse fee (buyer pays)
- $500M · 5.5%
- Go-shop
- —
- Financing
- No financing condition
Advisors
- To the acquirer
- Not disclosed
- To the target
- Centerview, Jefferies
- Centerview fee
- $50.0M
- Jefferies fee
- $50.0M
Sector context · Healthcare
- Comparable deals
- 91 in the prior 24 months
- Premium
- 27.0% vs. 67.0% sector median
- EV / Adj. EBITDA
- Sector median 14.5x
- Break fee
- 3.5% vs. 3.5% sector median
Timeline
- AnnouncedJun 2, 2025
- Tender offerJun 17, 2025
- ClosedJul 18, 2025
Valuation · fairness opinions
Trading comparablesCenterview$72.50$123.70
Precedent transactionsCenterview$103.40$171.75
Discounted cash flowCenterview$115.80$148.50
Analyst price targetsCenterview$83.00$167.00
Premiums paidCenterview$136.80$187.50
Trading comparablesJefferies$59.15$136.25
Trading comparablesJefferies$103.40$171.75
Discounted cash flowJefferies$112.50$143.65
Analyst price targetsJefferies$83.00$167.00
Offer $129.00
Implied value per Blueprint Medicines Corp share by analysis, from Centerview and Jefferies · DCF discount rate 11%–13%.